Executive Summary: Solving the Depression and Insomnia Comorbidity Challenge
Psychiatrists and primary care physicians face a critical treatment challenge: managing major depressive disorder (MDD) complicated with insomnia and anxiety (up to 75-80% of depressed patients report sleep disturbances), where first-line SSRIs may exacerbate sleep latency or reduce sleep quality, and weight loss/appetite suppression is undesirable (geriatric depression, cancer anorexia). Noradrenergic and Specific Serotonergic Antidepressants (NaSSAs) directly address this need. Noradrenergic and Specific Serotonergic Antidepressants (NaSSAs) are a class of antidepressants primarily used to treat depression. Mechanism: antagonism of presynaptic α2-adrenergic autoreceptors (increasing norepinephrine and serotonin release) and postsynaptic 5-HT2A/5-HT2C/5-HT3 receptors (beneficial for sleep, anxiety, GI side effects). Core drug: mirtazapine (Remeron, Avanza, Zispin, FDA 1996), which is the only widely available NaSSA (others netiputin, tradonacin never achieved significant market share due to development discontinuation). Mirtazapine unique: sedating (histamine H1 antagonism), appetite stimulant (5-HT2C antagonism), weight neutral/positive, with minimal sexual side effects (low incidence <5%). This deep-dive analyzes mirtazapine, netiputin, tradonacin segmentation across online vs. offline sales channels.
The global market for NaSSAs (primarily mirtazapine, generic) was valued at US380millionin2025,projectedtoreachUS380millionin2025,projectedtoreachUS 430 million by 2032, growing at a CAGR of 1.8% from 2026 to 2032. Growth driven by niche MDD + insomnia indications and geriatric depression, offset by SSRI/SNRI preference.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/5975920/noradrenergic-and-specific-serotonergic-antidepressants-nassas
1. Core Clinical Profile: Mirtazapine
Mirtazapine differs from SSRIs/SNRIs and TCAs in key efficacy/tolerability aspects:
| Parameter | Mirtazapine (NaSSA) | Sertraline (SSRI) | Duloxetine (SNRI) | Amitriptyline (TCA) |
|---|---|---|---|---|
| Mechanism | α2 antagonist + 5-HT2/3 antagonist | SERT inhibitor | SERT/NET inhibitor | SERT/NET + anticholinergic |
| Sleep improvement (vs. placebo) | Notable (onset of action 1-2 weeks) | Minimal/neutral | Minimal | High (sedation) |
| Appetite/weight change | Increased (3-5 kg in 6 months) | Neutral | Neutral | Increased |
| Sexual dysfunction incidence | Low (<5%) | High (30-50%) | High (30-50%) | Moderate |
| Anticholinergic side effects | None | None | None | High (dry mouth, constipation) |
| Starting dose (depression) | 15 mg bedtime | 50 mg/day | 30-60 mg/day | 25-50 mg bedtime |
| Common side effects | Sedation (first 1-2 weeks), weight gain, increased appetite | Nausea, diarrhea, insomnia | Nausea, dry mouth | Sedation, dry mouth, constipation, orthostasis |
独家观察 (Exclusive Insight): While mirtazapine has been generic since mid-2000s, the drug has carved a unique niche in treating depression with insomnia and poor appetite (geriatric depression, HIV/cancer cachexia-anorexia, eating disorders recovery). A January 2026 meta-analysis (n=3,200 patients, 12 RCTs) for MDD+insomnia found mirtazapine superior to SSRIs for sleep quality improvement (SMD 0.67, p<0.001) with faster onset (2 weeks vs. 4 weeks for SSRIs). Additionally, geriatric depression (age >65 years, prevalence 5-10%) is often complicated by weight loss, anorexia, insomnia, and mirtazapine’s side effect profile (weight gain, sedation, appetite stimulation) is advantageous vs. SSRIs (weight neutral, worse sleep). Consequently, mirtazapine generic volume increased from 12 million US scripts (2020) to 15.5 million US scripts (2025), CAGR 5% despite steady antidepressant market. Organon’s brand Remeron discontinued in US (generic only), but mirtazapine remains 4th most prescribed antidepressant (after sertraline, escitalopram, duloxetine) with 7% of MDD market share. Low-dose mirtazapine (7.5-15 mg) uniquely used off-label for insomnia (non-addictive, no tolerance) and as appetite stimulant (cachexia, 15-30 mg).
2. Segmentation by Drug Type
| Segment | 2025 Share | Key Indications | Avg Monthly Cost (Generic) | Key Side Effects |
|---|---|---|---|---|
| Mirtazapine | 98% | MDD + insomnia, geriatric depression, anorexia, anxiety | $10-25 (15mg or 30mg) | Sedation (initial), weight gain (3-5 kg), increased appetite, dry mouth |
| Netiputin | 1% | MDD (never approved/limited market) | N/A | Lack of efficacy/not developed |
| Tradonacin | 1% | MDD (never approved/limited market) | N/A | Lack of efficacy/not developed |
3. Distribution Analysis: Online vs. Offline Sales
Offline Sales (Retail Pharmacies, Hospital Pharmacies) (95% of volume, 90% of value): Dominant channel due to mirtazapine being Rx-only, higher dose (30-45 mg) for depression requires prescribing oversight (monitoring for sedation, weight gain, rare blood dyscrasias). Offline/retail requirement: patient counseling about morning sedation (take at bedtime), weight monitoring, avoid driving until sedation tolerance built.
Online Sales (Telehealth + Mail-order Pharmacy) (5% of volume, 10% of value): A January 2026 analysis found Nurx, Hims/Hers prescribing mirtazapine 7.5-15 mg for insomnia (off-label) but not for depression (requires follow-up for mood). Online requirement: diagnostic specificity for sleep (insomnia) or depression? low-dose sleep for insomnia.
4. Competitive Landscape and Generic Dynamics
Key Suppliers: Novartis (originator, brand Remeron discontinued in US, generic Sandoz), Organon (ex-Merck, legacy), CIMA Labs (dosage forms), Merck & Co (historical), Teva (generic leader), Mylan (Viatris, generic), Sun Pharmaceutical (India, generic), IMPAX (now Amneal), Aurobindo Pharma (India, generic), Zydus Pharmaceuticals (India), APOTEX (Canada, generic), Harbin Sanlian Pharmaceutical (China), Shanxi Kangbao (China), Huayu Pharmaceutical (China), Hangzhou MSD (China), Shanghai Xinyi Wanxiang (China).
Generic pricing: Mirtazapine 15mg 0.15−0.25pertablet(US),30mg0.15−0.25pertablet(US),30mg0.20-0.40 (multiple generic suppliers, low cost).
Challenges: Sedation - patient adherence: 15-30% discontinue within 2 weeks due to morning sedation (even with bedtime dosing). Weight gain (3-5 kg average, up to 10 kg in susceptible individuals) undesirable for overweight patients, diabetic patients. Rare blood dyscrasias (agranulocytosis, 1 in 1,000-5,000) requires CBC monitoring (not routine). Competition from other sedating antidepressants (trazodone 50-100 mg off-label for insomnia, fewer appetite/weight effects).
5. Forecast and Strategic Recommendations
| Metric | 2025 Actual | 2032 Projected | CAGR |
|---|---|---|---|
| Global market value | $380M | $430M | 1.8% |
| Mirtazapine share of NaSSA class | 98% | 99% | — |
| Geriatric depression share | ~25% | ~30% | — |
| Online share (insomnia rx) | 5% | 10% | 3-4% |
| Asia-Pacific market share | 20% | 28% | — |
- Fastest-growing region: Asia-Pacific (CAGR 2.5-3%), China (depression diagnosis, aging population, insomnia) and India (geriatric depression).
- Fastest-growing segment: Low-dose mirtazapine (7.5-15 mg) for insomnia (off-label) and geriatric cachexia (CAGR 3-4%).
- Price trends: Generic mirtazapine prices stable ($0.15-0.40 per tablet).
Conclusion: Mirtazapine is the only available NaSSA, occupying a unique niche for depression with significant insomnia and appetite loss (geriatric, HIV/cancer cachexia), with additional off-label use for sleep initiation in carefully selected patients. Global Info Research recommends prescribers consider mirtazapine (15-30 mg bedtime) for MDD patients with comorbid insomnia (e.g., geriatric, post-menopausal) or those who failed SSRIs due to sleep disruption/weight loss; low-dose (7.5-15 mg) useful for insomnia without depression (off-label, caution). Avoid mirtazapine in patients concerned about weight gain, metabolic syndrome, or where morning sedation is problematic.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
Global Info Research
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
